RALEIGH, N.C., May 25, 2016 (GLOBE NEWSWIRE) — INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization (CRO), today announced the relocation and expansion of its Osaka, Japan office in support of the Company’s long-term growth strategy both in Japan and across the Asia/Pacific region. Since the beginning of 2015 INC Research’s Japanese operations have more than tripled their employee headcount and expect continued strong growth. The new Osaka office further expands the Company’s presence in the Asia/Pacific region to provide its global drug development customers with expanded access to Japan, the world’s second largest pharmaceutical market and a valued destination for regional and global clinical trials. The Company’s presence in Japan also is supported by an office in the Shinagawa ward in Tokyo.

“Since establishing a strategic R&D presence in Japan, INC Research has experienced an exciting and notable period of initial growth,” said Miranda Porter, PhD, Senior Vice President, Clinical Development, Tokyo, who provides overall leadership for the Company’s Japan operations. “Our goal is to be the global ‘CRO of Choice’ in Japan, not only for customers but for employees as well. Our Japanese presence combines INC Research’s global expertise and therapeutically-aligned delivery model along with local experience and knowledge regarding Japan’s regulatory, healthcare, clinical trial site and cultural environments.  This unique combination allows us to provide quality services to customers seeking to conduct global and regional studies in Japan, and also to attract exceptional Japanese employees who are interested in the opportunity to work for a global CRO. We look forward to the continued growth of INC Research within Japan.”

Video from the opening of the INC Research Osaka office is available at https://www.youtube.com/watch?v=GqwZz1Ty2yM.

INC Research’s unique approach to the Japan market leverages the Company’s established global expertise, innovative Trusted Process® project management methodology and strong relationships with study sites. Local operations also feature English-speaking management, regulatory and therapeutic staff with experience delivering quality trials with full-service capabilities that balance innovation and respect for Japan-specific nuances. In addition to having a bilingual leadership team based in Japan, INC Research employs both project management and CRA staff in all key service areas, including study start-up, biometrics, biostatistics, project management, medical monitoring, safety and pharmacovigilance, medical writing, and quality assurance. The core teams at both the Osaka and Tokyo offices offer decades of experience managing local and global clinical trials within Japan across a wide array of therapeutic indications, with notable experience in CNS and oncology clinical development as well as FSP relationships.

The new Osaka office is located at 10th Floor Umeda Daibiru, 3-3-10 Umeda, Kita-ku, Osaka- Shi, Osaka 530-0001 and was chosen for its convenient location and proximity to the region’s bullet train and major drug development areas.

INC Research currently has 19 offices throughout the Asia/Pacific region in addition to Japan including offices in China, India, Australia, Singapore, Philippines, South Korea, Taiwan, Hong Kong, Malaysia, Thailand, Indonesia and New Zealand. The Company has a long history of providing Phase I to IV clinical development services in the Asia/Pacific region, conducting more than 1,800 studies across a broad range of therapeutic areas. For more information on INC Research’s clinical trial services and experience in Japan, please call +81-3-6837-5400 or visit INC’s Japanese language website at http://incresearch.com/jp.

About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization (“CRO”) providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.  Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market.  The Company was named “Best Contract Research Organization” in December 2015 by an independent panel for Scrip Intelligence, and ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey.  INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries.

Investor Relations Contact:
Ronnie Speight
Vice President, Investor Relations
Phone: +1 (919) 745-2745
Email: Investor.Relations@incresearch.com

Press/Media Contact:
Lori Dorer
Senior Director, Corporate Communications
Phone: +1 (513) 763-1380
Email: Corporate.Communications@incresearch.com